Anastrozole Tablet
Product Images NDC 50268-075

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 50268-075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1mg (075 15)

ANASTROZOLE 1 mg tablets unit dose packaging label. The label displays the product name, strength, and dosage form along with 'Rx Only' and package size of 50 tablets (5 x 10). It includes barcode and storage instructions at controlled room temperature. Labeler AvPAK is noted with manufacturing details and warnings to keep out of reach of children.*

FDA Label Image

Chemical Structure (Anastrozole 01)

Chemical structure of anastrozole, depicting its molecular framework with nitrogen-containing triazole and substituted benzene rings as part of the molecule.*

FDA Label Image

Figure 1 (Anastrozole 02)

A Kaplan-Meier survival curve chart comparing disease-free survival over months between patients treated with anastrozole and tamoxifen. The y-axis represents the proportion of patients alive and disease-free, and the x-axis represents disease-free survival time in months, ranging from 0 to 90. The legend distinguishes anastrozole with a dashed line and tamoxifen with a solid line. Below the x-axis, the number of patients at risk is listed at various time points for both treatments.*

FDA Label Image

Figure 2 (Anastrozole 03)

A line graph showing disease-free survival over time in months for treatments with anastrozole and tamoxifen. The y-axis represents the proportion of patients alive and disease-free, ranging from 0 to 1. The x-axis spans 0 to 90 months. Patient numbers at risk for each treatment are listed below the x-axis across different time points.*

FDA Label Image

Figure 3 (Anastrozole 04)

A Kaplan-Meier survival curve chart comparing the proportion event-free over time (months) between Anastrozole and Tamoxifen treatments. The x-axis represents time to event in months up to 120 months, and the y-axis shows the proportion event-free ranging from 0.50 to 1.00. The chart includes a legend for randomised treatments and a table showing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 4 (Anastrozole 05)

Kaplan-Meier curve chart depicting the proportion of patients event free over time in months for two randomized treatments: Anastrozole and Tamoxifen. The x-axis shows time to event in months up to 120, and the y-axis shows the proportion event free from 0.50 to 1.00. Below the graph is a table showing the number of patients at risk for each treatment group at specific time points.*

FDA Label Image

Figure 5 (Anastrozole 06)

A Kaplan-Meier survival curve comparing time to progression in months between two randomized treatments: anastrozole and tamoxifen. The y-axis shows the proportion not progressing, while the x-axis indicates time in months, with patient numbers at risk listed below.*

FDA Label Image

Figure 6 (Anastrozole 07)

A Kaplan-Meier survival curve chart showing the proportion of patients not progressing over time in months, comparing two randomized treatments: Anastrozole and Tamoxifen. The chart includes the number of patients at risk at various time points from 0 to 40 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.